In the last few years, three CDK4/6 inhibitors (i.e., palbociclib, ribociclib, abemaciclib) have been approved for the treatment of patients with metastatic HR+/HER2- breast cancer in combination with endocrine therapy1–11. This evidence concerns the gene ERBB2 and breast carcinoma.